Skip to main
IMCR
IMCR logo

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 17%
Sell 0%
Strong Sell 6%

Bulls say

Immunocore Holdings PLC is positioned favorably due to its strong early sales and rapid market penetration of its leading product, KIMMTRAK, which has demonstrated a significant survival benefit in treating metastatic uveal melanoma. The company's projected increases in the probability of success for its clinical candidates, particularly IMC-F106C and its application in non-small cell lung cancer (NSCLC), underscore the potential for enhanced product development and a robust pipeline across oncology and infectious diseases. Additionally, the advancing research in HIV treatment, particularly with IMC-M113V, highlights Immunocore's commitment to innovative therapies, suggesting a promising trajectory for its clinical programs and overall market presence.

Bears say

Immunocore Holdings faces significant uncertainty regarding the clinical efficacy of its drug candidates, particularly the IMC-F106C, which may yield minimal clinical benefit in specific cancer indications, thereby projecting a negative outlook with an implied decline in stock value. The company's pipeline development is further complicated by challenges associated with treatment safety, scalability, and accessibility, which could hinder the potential success of additional candidates beyond its existing platforms. Additionally, the intricacies of HIV treatment, including mutational escape and immune response exhaustion, raise doubts about the effectiveness of its IMC-M113V candidate, contributing to a cautious investment sentiment as investors weigh these risks against future revenue potential.

Immunocore Holdings (IMCR) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 17% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 18 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.61, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.61, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.